Lowest Price Guaranteed From USD 3,499
There are many different forms of retinitis pigmentosa and, being an orphan indication, it is safe to consider that drug / therapy developers working in this domain could receive the breakthrough designation, fast track designation and accelerated approval from regulatory authorities. Moreover, the pricing of the drugs is likely to reflect the likely opportunity in this area.
-Senior Vice President, a US based drug developer
The global back of the eye disorders market is expected to be worth $22.9 billion by 2030. According to the World Health Organization, close to 250 million individuals, including 36 million blind people, presently suffer from some form of vision impairment. Further, a recent study published in September 2017 estimates that the number of blind people is likely to increase to 38.5 million, by 2020, and to 115 million, by 2050. Current projections also indicate that, in the US alone, the total economic burden related to vision loss is expected to reach approximately USD 715 billion by 2050. In fact, chronic eye diseases are considered to be one of the main causes of vision loss globally, and an estimated 90% cases of visual impairment are reported to be caused due to such conditions. It is worth highlighting that a significant portion of these chronic ophthalmological disorders are clinical conditions related to the back of the eye.
The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster drugs, such as Lucentis® and Eylea®, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks that have an adverse impact on their therapeutic potential and adoption. Further, there are no treatment approaches available for a number of ophthalmological indications, such as dry age related macular degeneration (dry AMD), retinitis pigmentosa (RP) and leber congenital amaurosis. In order to overcome these challenges, various stakeholders are engaged in the development of novel therapeutic approaches. With the entry of several start-ups that are driving the innovation in back of the eye disorders market, the pipeline has several novel product candidates in various stages of development. Companies are steadily collaborating to develop and commercialize their products globally, in-license intellectual property to design new treatment modalities and advance research initiatives in back of the eye disorders market.
Several recent developments have taken place in back of the eye disorders market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Back of the Eye Disorders Market: Novel Drugs and Delivery Technologies, 2017-2030’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the back of the eye disorders market. The focus of this market research report is on the applications and the likely evolution of novel treatment options (excluding steroids and corticosteroids) in the mid to long term. The evolving market has its hopes pinned on the efforts of multiple start-ups, small and large-sized companies. Amongst other elements, the market research report features:
The key objective of back of the eye disorders market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for back of the eye disorders market during the forecast period. Based on various parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the forecast period 2017-2030. To account for the uncertainties associated with the development of novel drugs and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in back of the eye disorders market. These include Elise Brownell (Senior Vice President of Operations and Project Management, Amarantus Bioscience), Quinton Oswald (President and CEO, Neurotech Pharmaceuticals) and Samantha Cobb (CEO, AdAlta). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.